Global Testing Alliance Leverage the Mayo Clinic Laboratories partnership to commercialize PhageBank susceptibility assays globally, enabling hospitals to rapidly identify compatible phages for multi-drug resistant infections. Expand the testing network using sequencing capabilities (Illumina, Oxford Nanopore) to profile phage susceptibility and match patients to therapies. Target large health systems, academic medical centers, and regional labs for integrated diagnostic and therapeutic adoption of phage therapy.

Pipeline Expansion Pipeline expansion with BX211 for diabetic foot osteomyelitis signals growth beyond the initial program. This provides an opportunity to pursue co-development or licensing deals with hospitals and wound-care providers, engage payers with potential cost-savings and reduced antibiotic use, and accelerate market access once validated by Phase 2 results.

Investor Momentum Investor-backed momentum suggests strong fundraising appetite for collaborations. The AMR Action Fund investment and 2022 financing rounds indicate a favorable environment for joint development, milestone-based partnerships, and potential non-dilutive funding to support trials and real-world data generation.

Regulatory Traction Regulatory traction through FDA emergency IND allowances demonstrates clinical viability and regulatory flexibility. Use this to structure expanded access programs and prospective registries with partner sites, generate real-world evidence, and build payer case for broader reimbursement.

Market Access Network Strategic market access networks shown by Hadassah collaboration and Mayo Clinic Labs distribution enable faster scale. Expand with additional hospital networks, academic centers, and philanthropic partners to accelerate adoption, while developing compelling value propositions for payers around MDR infection management and reduced antibiotic usage.